Context: Premature ovarian insufficiency (POI) is highly heterogeneous, both in phenotype and etiology. They are not yet clearly stated and correlated.
more concerns, particularly given the increase of environment pollutants, social stress, childbearing postponement, and prolonged survival after gonadotoxic treatments (2) (3) (4) .
POI is highly heterogeneous, both in phenotype and etiology (5, 6) . It is not merely early menopause, nor is it permanent. In fact, the ovarian function is in a continuum of ovarian impairment in POI. Approximately 50% of women with POI experience intermittent and unpredictable resumption of ovarian activity; ovulation or spontaneous pregnancy, even years after diagnosis, occasionally occurs (7) . POI encompasses a wide spectrum of causes, including genetic, autoimmune, infectious, or iatrogenic, whereas the majority remains unknown (6) . Furthermore, no comprehensive understanding of the clinical spectrum in terms of different etiologies is currently available.
In the current study, clinical characteristics of a large, well-phenotyped cohort of women with POI were defined and further stratified for different etiologies to provide clues for optimal fertility consulting.
Materials and Methods

Patients
A total of 1227 women with POI were recruited and systemically evaluated at the Center for Reproductive Medicine, Shandong University, China. The study was approved by the Ethical Committee of Reproductive Medicine of Shandong University. Written informed consents were obtained from all participants. Inclusion criteria included primary amenorrhea (PA) or secondary amenorrhea (SA) for at least 4 months, and serum follicle-stimulating hormone (FSH) .40 IU/L (on two occasions .1 month apart) before age 40. The standardized evaluation consisted of clinical history, physical examination, reproductive characteristics, genetic, autoimmune, and iatrogenic factors, and ovarian biopsy in a subset of patients. A detailed questionnaire covering demographic characteristics, gynecological and obstetric data, and family/surgery/disease history was recorded. Family history was considered "positive" if another first-or second-degree relative had either POI or early menopause (menopause #45 years). According to the duration of reproductive age (years between menarche and amenorrhea), patients with SA were further divided into four subgroups: #5 years (n = 182); 6 to 10 years (n = 243); 11 to 15 years (n = 220); and .15 years (n = 176).
Hormone measurement
Blood was sampled on days 2 to 4 of menstrual cycle or randomly (for women not menstruating frequently). FSH, LH, estradiol, prolactin, and total testosterone were measured by chemiluminescence immunoassay (Roche Diagnostics, Mannheim, Germany). Anti-Müllerian hormone (AMH) and Inhibin-B were detected by enzyme-linked immunosorbent assay (Kangrun Biotech, Guangzhou, China). The intra-assay and interassay coefficients of variation were ,10%.
Pelvic ultrasonography
Gynecological examination and transvaginal ultrasonography were routinely conducted. The ovarian surface area (S = length 3 width 3 0.8) and antral follicle counts were recorded. Antral follicle count was defined as the number of follicles 2 to 10 mm in early follicular phase.
Ovarian histology
Ovarian biopsy was performed with laparoscope. For each patient, bilateral biopsies (from January 2013 to November 2014) or left biopsy (after November 2014) were sampled and fixed in 4% paraformaldehyde. After embedded and serially sectioned (5 mm), three to four (one out of every five) sections were stained with hematoxylin/eosin and examined.
Genetic evaluation
Genetic evaluation included karyotype analysis, CGG repeats in FMR1 gene, and mutation screening in candidate genes. Karyotype was analyzed on GTG-banded metaphase chromosomes (400-to 450-band resolutions) (8) . The FMR1 gene was amplified with fluorescence-labeled primers, and the CGG repeats of two alleles were counted by capillary electrophoresis (9) . Mutations of candidate genes (e.g., FIGLA, NOBOX, GDF9, SOHLH1, SOHLH2, WT1, NR5A1, PGRMC1, FSHR, DMC1, MCM8, MSH5, and CSB-PGBD3) were screened by Sanger sequencing using specific primers (10, 11) .
Autoimmune antibody detection
Adrenal cortex autoantibody (AAA) titers were detected by indirect immunofluorescence assay on monkey adrenal gland sections (Euroimmun, Lübeck, Germany). Non-organ-specific antibodies, anti-nuclear antibody, anti-cardiolipin antibody, and anti-double-stranded DNA antibody were determined by enzyme-linked immunosorbent assay (Orgentec, Mainz, Germany).
Statistical analysis SPSS 23.0 was used for statistical analysis (SPSS Inc.). Continuous data in normality distribution were expressed as mean 6 standard deviation and compared by Student t test or one-way analysis of variance; otherwise, data were presented as median (quartile interval) and compared with Mann-Whitney U test. The difference of categorical data in percentage was compared by x 2 test or Fisher's exact test. Correlation analysis was performed for variables among different reproductive periods. P , 0.05 was considered statistically significant. P value was corrected by Bonferroni adjustment within multiple comparisons.
Results
Baseline characteristics
After excluding 272 women with incomplete data in the database, the current study comprised 955 women with POI, and average age at recruitment was 29.28 6 4.75 years. Somatic anomalies (webbed neck and cubitus valgus) were found in five cases and mental retardation in three cases. Characteristics of our POI cohort are summarized in Table 1 ), especially for patients with PA (P , 0.001). Presence of follicles was found in approximately 38.36% of patients with visible ovaries, with the prevalence much higher in patients with SA than PA (39.59% vs 25.76%; P , 0.05) ( Table 1 ). There were 31 cases (4.72%) with SA who had follicles 10 mm or larger. Compared with SA patients without follicles, those with follicles were older at recruitment and experienced later onset of POI (P # 0.001). The presence of follicles was also associated with lower FSH, increased estradiol, and ovarian surface area (P , 0.05) (Supplemental Table 1 ).
A total of 86 patients with SA and visible ovaries in sonography underwent ovarian biopsies. The majority showed bilateral small or steak ovaries with hard texture. Most ovaries only contained fibrous connective tissue covered by cuboidal epithelium, with atretic follicles or corpora albicantia occasionally (Supplemental Fig. 1 ). The presence of follicles, either quiescent or growing, was detected in 13 (15.12%) cases. A follicular reserve with primordial follicles was found in 8 cases, primary follicles in 11, secondary follicles in 9, and early antral follicles in 4 (Supplemental Fig. 1 ). No differences of phenotypic parameters were observed in patients with or without follicles (P . 0.05) (Supplemental Table 2 ). No significant concordance in the frequency of visible follicles between ultrasound and biopsy data was found (concordance coefficient k = 0.038; P . 0.05).
Pregnancy history before POI diagnosis
Among patients with pregnancy history before POI diagnosis, 188 (22.9%) women with SA had a total of d Data of 50 patients with AMH above detection limit is shown.
e Data of 31 patients with Inhibin-B above detection limit is shown.
377 pregnancies. No pregnancies occurred in any of the PA patients. 32.64% (110/337) resulted in term delivery, and 10.98% (37/337) experienced spontaneous miscarriage. Later onset of menstrual irregularity and amenorrhea was observed in patients who had been pregnant in the past compared to those who had not (P , 0.001) (Supplemental Table 3 ; Fig. 1 ). As expected, the longer duration of reproductive age, the higher prevalence of pregnancy, and parity were observed (P , 0.001) (Supplemental Table 6 ).
Family history
Family history, either POI or early menopause, was reported in 12.25% (117/955) of patients, including 103 mothers, 4 maternal aunts, and 10 siblings. No difference in the rate of positive family history was found between patients with PA and SA (P = 0.687) ( Table 1) . Among patients with SA, although no difference of age at menarche was found between patients with and without family history, patients with family history experienced irregular menses and amenorrhea much later than those sporadic (P , 0.01) (Supplemental Table 4 ; Fig. 1 ). The later the amenorrhea occurred, the higher the frequency of positive family history was observed (P , 0.05) (Supplemental Table 6 ). Thirty-three individuals with pregnancy (32.35%) had family history of POI compared with 155 individuals (21.56%) in sporadic cases (P , 0.05) (Supplemental Table 4 ).
Karyotype analysis
Karyotype was analyzed in 700 POI cases, and 14.71% presented abnormal. Of these anomalies, 94 (91.26%) involved the X chromosome; 3 (2.91%) involved only autosomes; and 6 (5.83%) were nonmosaic 46,XY and 45,X/46,XY mosaicism. The frequency of karyotypic aberrations was significantly higher in patients with PA than SA (30.70%, 35/114 vs 11.60%, 68/ 586; P , 0.001) and higher in sporadic cases than those with family histories (15.80%, 97/614 vs 7.23%, 6/83; P , 0.05). SA patients with abnormal karyotype experienced menarche and irregularity later than those with normal karyotype (P , 0.01), whereas no difference was observed with age of amenorrhea (P = 0.091) (Supplemental Table 5 ; Fig. 1 ). Interestingly, patients with a longer reproductive period tended to have decreased chromosomal abnormality (P = 0.072) (Supplemental Table 6 ). The prevalence of pregnancy was also SA patients with (black bar) or without (white bar) chromosomal abnormality; etiology: genetic (black bar), autoimmune (white bar), iatrogenic (striped bar), or idiopathic (boxed bar). Data were expressed as mean 6 standard deviation. *P , 0.05; **P , 0.01; ***P , 0.001.
significantly lower in patients with abnormal karyotype (P , 0.05) (Supplemental Table 5 ).
Gene mutations
Candidate genes associated with folliculogenesis/ oogenesis (e.g., FIGLA, NOBOX, GDF9, SOHLH1, SOHLH2, WT1, and NR5A1), endocrine hormone/ receptor (PGRMC1 and FSHR), DNA damage repair/ meiosis (e.g., DMC1, MCM8, MSH5, and CSB-PGBD3), and premutation of FMR1 were screened in different subsets of the idiopathic POI cohort with normal karyotype (Table 2 ). FMR1 premutation (CGG repeats 55 to 199) was observed in only two patients (0.53%, 2/379) and none of the matched controls. Both alleles in POI cases demonstrated a small but significant shift toward a single additional CGG repeat in the FMR1 gene (P , 0.001). Among other candidate genes, FIGLA, NOBOX, WT1, NR5A1, FSHR, MCM8, MSH5, and CSB-PGBD3 were proven causatively by functional validation experiments.
Causative genes MSH5 and CSB-PGBD3 were first identified by whole-exome sequencing in two POI pedigrees, and their deficiencies were related to impaired DNA repair (Table 1 ; Supplemental Fig. 2 ). Given the novel nonsynonymous variants, if any were identified, each gene deficiency generally explains at most 2%. All variants were heterozygous except the MSH5 mutation in two POI siblings. None carried two different or compound mutations. Therefore, in total, known gene mutations could account for less than 3.29% (23 cases) of patients with POI.
Autoimmune factors
A total of 38 patients with SA (6.02%, 38/631) presented with autoimmune disorders, including hypothyroidism or Hashimoto thyroiditis (n = 17), Graves disease (n = 8), psoriasis (n = 5), rheumatoid arthritis (n = 4), systemic lupus erythematosus (n = 2), takayasuarteritis (n = 1), and allergic purpura (n = 1). Autoantibody data were available for 250 idiopathic cases with SA (data 
Iatrogenic factors
Acquired iatrogenic factors accounted for 7.29% (46/ 631) of cases with SA. Before the onset of ovarian insufficiency, 12 patients (1.90%) experienced pelvic radiation or chemotherapy exposure, whereas 34 (5.39%) underwent ovarian surgery, including 4 unilateral oophorectomy, 25 ovarian cystectomy (20 unilateral, 5 bilateral), and 5 unilateral oophorectomy with contralateral cystectomy. The pathological type of ovarian cysts included endometriosis cysts, teratomas, and serous or mucinous cystadenomas. Menstrual cycles were recalled in 20 patients (mean age, 25.45 6 5.65 years) with regular periods before ovarian surgeries (9 bilateral and 11 unilateral). It took approximately 3 years (0 to 10 years; 95% CI, 1.49 to 4.61 years) to develop amenorrhea after surgeries, and almost one-half (45%, 9/20) displayed ovarian insufficiency within 1 year. No significant differences, in terms of duration from surgery to amenorrhea and the percentage of patients developing POI within 1 year after surgeries, were observed between patients with bilateral and unilateral surgery. The age receiving surgery was positively correlated with the age of amenorrhea (r = 0.817, P , 0.001).
The known plausible etiologies of POI with SA were assessed and consisted of genetic (13.15%), autoimmune (12.04%), and iatrogenic (7.29%), with approximately 68% remaining idiopathic. The detailed distribution is outlined in Table 3 . There were significant differences of age at menarche/amenorrhea/recruitment and prevalence of previous pregnancy among those four categories (all P , 0.05; Fig. 1 ). Patients with known genetic anomalies experienced a trend toward later menarche, earlier amenorrhea, and consequently earlier diagnosis and lower prevalence of pregnancy compared with those with autoimmune or iatrogenic etiologies. No significant difference existed between patients with autoimmune and iatrogenic etiology.
Discussion
POI imposes a great challenge on women's fertility and lifelong health. It is of increasing clinical importance given its rising prevalence. However, it remains poorly understood and under-researched. Controversy persists regarding its nomenclature and recruitment criteria; high heterogeneity in etiology and phenotype as well as absence of early diagnosis and optimal treatment regimens Clinical phenotypes POI is variable in its clinical presentation. PA may represent the most severe defect in ovarian function, characterized by early-onset, specific phenotype and high prevalence of chromosomal aberration. Women with SA had considerably shortened reproductive window (approximately 10 years). They experienced menarche 2 years later than that of general Chinese girls (approximately 12 years) (12) . And their menses ceased around age 25, within 2 years, and surprisingly more than 50% within 1 year, after irregularity occurred. This time frame is significantly shorter than the physiological interval of 5 to 10 years between onset of cycle irregularity and menopause (13) . This highlights the rapid decline of ovarian function in POI. It has been reported that earlier age at menarche was associated with earlier age at menopause because of increased frequency of ovulation (14) . However, our data, consistent with others (15, 16), did not show this relationship. Another concern was the delayed diagnosis. It took approximately 5 years for a confirmed diagnosis of POI after amenorrhea. Panay et al. (17) reported that 50% of women with amenorrhea had to consult three physicians before any ovarian reserve evaluation was performed. In another study, in 25% of women, the diagnosis of POI took more than 5 years (18) . Therefore, it is critical to evaluate the ovarian function in adolescents with late menarche or young women with irregular periods.
As expected, all patients exhibited typical endocrine profiles with continuously elevated gonadotropin and decreased estradiol. About 50% of patients manifested deficiency of testosterone. This is in agreement with the previous studies, which have shown that the production of ovarian testosterone was insufficient in POI (19, 20) . Recently, AMH and Inhibin-B have been suggested as early markers for diminished ovarian reserve impending POI (21) . However, given that our cohorts were already in the stage of ovarian failure, AMH and Inhibin-B were low or undetectable as reported previously (22, 23) .
Most ovaries in all patients with POI (71.57%), particularly in patients with PA (85.25%), were either undetectable or very small, lacking growing follicles. The presence of follicles might indicate the residual or resumption of ovarian function, especially with follicles larger than 10 mm. Patients with presence of follicles tended to experience menstrual disturbance later and had better hormone parameters and larger ovaries. Histologic analysis of ovarian biopsy has also been proposed.
However, given that small biopsies are not predictive of the whole nature, it is not standardized or routinely recommended as an invasive procedure (7). In our study, ovarian biopsy was performed in a small subset of SA patients with visible ovaries under ultrasonography. The presence of growing follicles was found in only 15.12% of patients, a lower prevalence compared with previous reports (24) . In addition, clinical characteristics did not differ between patients with or without follicles, nor was concordance found in follicular pattern at pelvic ultrasonography compared with ovarian biopsy. Therefore, our results reconfirm that ovarian biopsy is uninformative for evaluation and diagnosis. Nonetheless, ovarian biopsy, in the context of management, may be of therapeutic benefit given the success of in vitro culture of immature oocytes or primordial follicles (25) .
Extensive evidence has indicated a strong familial, and therefore genetic, component to POI (5, 6) . In our cohort, 12.3% had at least one affected relative, similar to what reported by Bachelot et al. (14%) (26) . POI women with affected relatives tended to experience menstrual disturbance and amenorrhea later and had more chance to get pregnant compared with sporadic POI. These data indicate considerably better ovarian function in women with family histories. Consistent with our findings, Bidet et al. (24) reported that positive family history was a good predictor for resumption of ovarian activity. Therefore, early diagnosis of familial POI will help in prediction of early menopause or POI, which would provide other reproductive choices of childbearing planning or freezing oocytes/embryos.
Plausible etiologies
Different etiologic factors and pathogenic mechanisms have been reviewed comprehensively (6, 27) ; however, phenotypic characteristics with different etiologies in POI remain elusive. In this study, known plausible etiologies were divided into genetic, autoimmune, and iatrogenic factors, while one-half remained idiopathic. Our results demonstrated that POI likely comprises different subtypes with different etiopathologies. Spontaneous genetic POI represents the most unique and severe phenotype of premature aging, distinct from that of autoimmune or iatrogenic induced.
The genetic factor has long been considered as a component of POI. Here we focused on chromosomal abnormalities and gene mutations. Chromosomal aberration is a common cause of POI, although percentages vary widely among reported series. By reviewing the five largest POI studies, a prevalence of 10% to 15% seems reasonable (8, (28) (29) (30) . The X chromosome defects, including numerical aberration and rearrangements, are an important factor for ovarian dysfunction (8) . The frequency of abnormality was much higher in patients with PA compared with SA, which was consistent with previous reports (30) . A higher prevalence of abnormalities is correlated with shorter reproductive windows and lower prevalence for pregnancy and parity, which confirms the important role played by two intact chromosomes for fecundity. More interestingly, chromosomal abnormality is more common in sporadic POI patients compared with those with affected relatives, suggesting that the majority of these anomalies are de novo rather than inherited, whereas gene deficiencies may account for most POI patients with family history.
POI is highly heterogeneous with no single underlying dominant gene deficiency (6, 27) . Taken together, over 80 candidate genes have been identified, and approximately 25% of genes were validated to be causative functionally (27) . These identified gene deficiencies account for only a small proportion of POI patients, and most of them had notable ethnic differences in mutation frequency. Our results that no perturbations, weak associations with low incidence, or no same variants existed in different individuals further confirmed the heterogeneity of its pathogenesis. Of note, the prevalence of FMR1 premutation in our cohort was considerably lower than previously reported (31) . Thus, FMR1 testing is not part of the workup of women with POI in our clinics as recommended in the United States and Europe (32, 33) . Furthermore, defects in different candidate genes may be responsible for different phenotypes. For instance, deficiency in genes involved in reduced primordial follicle pool is considered associated with PA, whereas those related to dysregulated folliculogenesis or accelerated depletion are more common in SA. It would be yet more desirable to classify POI on the basis of aberrant ovarian differentiation and folliculogenesis or screen distinct gene panels in a large phenotypically defined POI cohort with isolated or syndromic features, sporadic or familial forms, PA or SA, and early or later onset. Given the low yields of a single-candidate gene approach, identifying genes not isolated but interrelated functionally within pathways with next-generation sequencing and implementation of a systems approach is anticipated.
Autoimmune disturbances could contribute to a subset of POI (5% to 30%) (34, 35) . The ovary is a susceptible target of autoimmune attacks given its dynamics of folliculogenesis, ovulation, luteum formation, and dysgenesis. Once the autoimmune destruction initiates, ovarian follicles might be attacked and depleted prematurely, and consequently POI occurs. However, reliable diagnosis of autoimmune premature ovarian insufficiency (aPOI) remains elusive. POI occurs more frequently in women affected by autoimmune diseases and vice versa. Consistent with previous evidence (26, 35) , thyroiditis was the most common coexistent autoimmune disorder, followed by psoriasis and rheumatoid arthritis in this study. Common antigens among different organs and overall autoimmune misbalance might exist in POI. Presence of serum autoantibodies represents potential markers to predict the risk of POI (36) . The most promising indicators of aPOI are steroid cell autoantibodies and AAA, and the presence of steroid cell autoantibodies is almost exclusive in patients positive for AAA (37) . We found that the positive frequency of AAA was significantly higher in patients with POI, confirming its role as a potential marker for aPOI. However, no difference of reproductive characteristics was observed between AAA-positive and -negative patients. And both groups presented with atrophic ovaries in ovarian biopsy. Ovarian inflammation might be transient and not present by the late stage in our patients. Consistent with the biphasic nature of inflammation, an atrophic ovary remained long after the inflammation rapidly disappeared. Therefore, further examination in earlier, yet progressive, POI patients is warranted to elucidate the plausible autoimmune causes. Additionally, an autoimmune screen for thyroid and adrenal autoantibodies is essentially important for future surveillance of thyroid or adrenal deficiency in patients with POI.
With the advance of "oncofertility," iatrogenic ovarian damage is increasingly common. The well-documented iatrogenic causes of POI are chemotherapy, pelvic radiotherapy, and immunosuppressive agents. These therapies significantly induce and accelerate apoptosis or atresia of ovarian follicles. Pelvic surgery is another risk factor for ovarian insufficiency (7, 38) given its deleterious effect on the follicle pool and ovarian blood supply. Our data demonstrated that POI occurred within 2 years after the surgery, which was faster than previously reported (39) . The earlier ovarian surgery was performed, the earlier amenorrhea occurred. Thus, fertility counseling is suggested to inform patients of the risk of ovarian dysfunction after surgery, and follow-up is recommended to monitor ovarian reserve.
Conclusion
Our results depict a comprehensive picture of clinical phenotype with different etiologies in women with POI; however, our study only involved patients with overt POI. Future studies, which longitudinally stage reproductive aging and incorporate patients at an earlier stage, are warranted for early diagnosis or to develop strategies that improve fertility. As the cause of POI still remains undetermined in a majority of patients, the pathogenesis and association with phenotype and risk prediction still need to be explored.
